GSK plc to acquire Nuvalent, Inc

GSK plc has agreed to acquire Nuvalent, Inc in a strategic acquisition valued at $10.6 billion. The transaction, announced and completed on 15 July 2026, involves full cash consideration. GSK is a United Kingdom-based healthcare company, while Nuvalent is a US-headquartered entity operating within the healthcare sector. This deal represents a significant capital deployment by the British pharmaceutical giant to expand its portfolio through the purchase of the American biotechnology firm. The equity value of the transaction stands at ten point six billion US dollars, reflecting the premium placed on Nuvalent’s assets and intellectual property. The immediate completion of the deal suggests a streamlined approval process and mutual agreement on the terms between the parties involved.

The acquisition marks a notable consolidation event in the global healthcare industry, bringing together two distinct entities under a single corporate umbrella. By acquiring Nuvalent, GSK plc integrates the target’s operations and research capabilities into its existing business structure. The all-cash nature of the deal avoids any dilution of GSK’s existing shareholder equity. As the transaction has already been completed, the integration phase is now underway. The deal is final, with no further regulatory hurdles pending. This move underscores the ongoing trend of large pharmaceutical firms acquiring innovative biotech companies to bolster their pipeline of future medicines.